
BioTechniques News
Beatrice Bowlby

Original story from Lund University (Sweden).
Researchers have identified a key role for the protein galectin-3 in shaping amyloid plaques in Alzheimer’s disease.
Researchers at Lund University (Sweden) have identified a key role for the protein galectin-3 in Alzheimer’s disease. The study shows that galectin-3 not only influences how the brain’s immune cells, known as microglia, react to the disease’s characteristic amyloid plaques. The protein also shapes the plaques themselves — and may contribute to the nerve damage that develops around them.
“This discovery provides new insights into the mechanisms of the disease and identifies galectin-3 as a potential future therapeutic target,” commented Lluís Camprubí-Ferrer, one of the study’s lead authors and a postdoctoral researcher at Lund University.
Alzheimer’s disease is characterized by accumulations of beta-amyloid (Aβ) in the brain. These proteins clump together to form plaques. In a previous study, the research team at Lund University showed for the first time that the protein galectin-3 increases in the brains of people with Alzheimer’s disease, and that removing the protein decreased inflammation in the brain. In this new study, the researchers have shown the direct relationship between galectin-3 and Aβ plaques. The results of the animal studies are clear-cut, showing a cause-and-effect relationship. The experiments on human tissue, from nine individuals, show a strong correlation.

CRISPR-A, organoids and autism: searching for a potential preventative
Using CRISPR activation methods in a mix of neuronal cell cultures and brain organoids, researchers may have found two targets for early developmental interventions to inhibit the development of autism spectrum disorder.
The new study shows that galectin-3 binds “with remarkable strength” to Aβ, and that it acts in two places at once. Outside the microglia it sits on the plaque itself, where it changes the shape of the amyloid fibers as they grow. Inside the microglia it sits in the lysosomes (the compartments where the cell breaks down what it has swallowed) where it steers how amyloid is processed. Galectin-3, the researchers conclude, is not merely present around the plaque — it actively shapes it.
“No one has previously shown what galectin-3 does to the plaque itself. We have observed that the protein binds to long protein strands known as amyloid fibrils, blocking one of the steps by which they multiply and altering their shape. In cell experiments, the fibrils reshaped by galectin-3 went on to damage nerve cells,” explained Camprubí-Ferrer.
The current study was carried out on both mice and human tissue, in collaboration with the University of Seville and the Instituto de Biomedicina de Sevilla (both Spain). When the researchers removed galectin-3 in mice with an Alzheimer’s-like disease, the plaques became smaller and more tightly packed. The surrounding nerve endings were damaged to a significantly lesser extent, and the immune cells (microglia) shifted from an aggressive, inflammatory state to a protective one.
“When we inactivated galectin-3, microglia transitioned from their harmful state to a state rich in the protective receptor TREM2, a protein that we know plays an important role in the brain’s immune defense and in the risk of Alzheimer’s disease,” shared Camprubí-Ferrer.
The results of the animal studies are clear-cut, showing a cause-and-effect relationship. The experiments on human tissue, from nine individuals, show a strong correlation. What the researchers cannot yet say is whether blocking galectin-3 helps patients. Only a clinical trial can provide an answer to that.
“This is important because current Alzheimer’s drugs target amyloid without helping to reduce inflammation in the brain. And galectin-3 is a protein that drugs can actually bind to,” explained Camprubí-Ferrer.
“And the timing is right. Drugs containing antibodies that break down amyloid have reached patients, but their modest effect has drawn attention to the brain’s immune response. That is where we can now fill in the gaps,” commented Tomas Deierborg, professor and leader of the Experimental Neuroinflammation research group at Lund University.
Tomas Deierborg finds it particularly encouraging that their early discoveries have now led to clinical trials. Just a few weeks ago, US regulators gave the go-ahead for a Phase 2 trial of an antibody that blocks galectin-3. “This demonstrates the clinical potential of our research findings,” concluded Deierborg.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
The post The protein that shapes the plaques: a novel therapeutic target for Alzheimer’s disease appeared first on BioTechniques.
Powered by WPeMatico
